IN2014DN06121A - - Google Patents

Info

Publication number
IN2014DN06121A
IN2014DN06121A IN6121DEN2014A IN2014DN06121A IN 2014DN06121 A IN2014DN06121 A IN 2014DN06121A IN 6121DEN2014 A IN6121DEN2014 A IN 6121DEN2014A IN 2014DN06121 A IN2014DN06121 A IN 2014DN06121A
Authority
IN
India
Prior art keywords
ethyleneimine
oligomer
concentration
aqueous solution
range
Prior art date
Application number
Inventor
Guy Casy
Barry Kingston Derham
Jan Jezek
Nikki Royle
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of IN2014DN06121A publication Critical patent/IN2014DN06121A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Peptides Or Proteins (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

The present invention provides an aqueous solution comprising an antibody protein at a concentration of at least about 10 mg/mL and an oligomer of ethyleneimine wherein the number of repeating units of ethyleneimine (n) in the oligomer is in the range n = 2 12.
IN6121DEN2014 2012-01-30 2013-01-30 IN2014DN06121A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261592323P 2012-01-30 2012-01-30
PCT/GB2013/050211 WO2013114112A2 (en) 2012-01-30 2013-01-30 Stabilized aqueous antibody compositions

Publications (1)

Publication Number Publication Date
IN2014DN06121A true IN2014DN06121A (en) 2015-08-14

Family

ID=47681959

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6121DEN2014 IN2014DN06121A (en) 2012-01-30 2013-01-30

Country Status (9)

Country Link
US (2) US10532098B2 (en)
EP (1) EP2809350B1 (en)
JP (1) JP2015506369A (en)
CN (1) CN104203282A (en)
CA (1) CA2861402C (en)
DK (1) DK2809350T3 (en)
ES (1) ES2705538T3 (en)
IN (1) IN2014DN06121A (en)
WO (1) WO2013114112A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809350B1 (en) 2012-01-30 2018-10-17 Arecor Limited Stabilized aqueous antibody compositions
KR102243196B1 (en) * 2016-02-19 2021-04-22 애버리 데니슨 코포레이션 Two-step method of manufacturing adhesive and related composition
GB201613896D0 (en) 2016-08-12 2016-09-28 Arecor Ltd Novel composition
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
WO2020055679A2 (en) * 2018-09-10 2020-03-19 Dow Global Technologies Llc A composition comprising a protein and a polyalkoxy fatty acyl surfactant

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
DE19726186A1 (en) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Complexes for the transport of nucleic acid into higher eukaryotic cells
DE19933024C2 (en) 1999-07-15 2003-03-13 Medinnova Ges Med Innovationen Cationic block copolymers
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP2330132B1 (en) * 2003-04-04 2013-08-14 Yeda Research and Development Co. Ltd. Antibodies against MMP2 or MMP9 and pharmaceutical compositions containing same useful for inhibiting activity of said metalloproteins
JP4701169B2 (en) 2003-06-30 2011-06-15 カンジ，インコーポレイテッド Adenovirus polymer encapsulation
US7022214B2 (en) * 2004-01-21 2006-04-04 Bio-Rad Laboratories, Inc. Carrier ampholytes of high pH range
EP1871806A2 (en) * 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
US20090011004A1 (en) 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US20080312174A1 (en) 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
BRPI0918988A2 (en) 2008-09-24 2015-12-01 Stabilitech Ltd methods for preserving a vaccine polypeptide and immunogen, and for preparing a vaccine, dry powder, preserved product, sealed vial, ampoule or syringe, use of an excipient, and vaccine.
JP2012510468A (en) * 2008-11-28 2012-05-10 アボット・ラボラトリーズ Stable antibody composition and method for stabilizing the same
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
EP2809350B1 (en) 2012-01-30 2018-10-17 Arecor Limited Stabilized aqueous antibody compositions

Also Published As

Publication number Publication date
WO2013114112A3 (en) 2013-11-07
EP2809350B1 (en) 2018-10-17
WO2013114112A2 (en) 2013-08-08
CA2861402C (en) 2021-10-12
US20150010548A1 (en) 2015-01-08
EP2809350A2 (en) 2014-12-10
ES2705538T3 (en) 2019-03-25
US10532098B2 (en) 2020-01-14
US20200138946A1 (en) 2020-05-07
JP2015506369A (en) 2015-03-02
US12016922B2 (en) 2024-06-25
CN104203282A (en) 2014-12-10
CA2861402A1 (en) 2013-08-08
DK2809350T3 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
IN2014DN06121A (en)
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
EA201890006A1 (en) APPLICATION OF THE EXOSOM FOR THE TREATMENT OF THE DISEASE
EA201590388A1 (en) METHODS OF TREATMENT OF Taupathy
EA201500314A1 (en) DOSAGE FORMS OF ENZALUTAMIDE
CY1119518T1 (en) MODIFIED TREATMENT ANTIGENS
EA201790378A1 (en) CONCLUDED IN LIPOSOM AFFINE MEDICINE
EA201590174A1 (en) IMMUNOCONGATES CONTAINING ANTI-CD22 ANTIBODIES
EA201300987A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING METHORMENE AND DPP-4 INHIBITOR OR SGLT-2 INHIBITOR
MY160552A (en) Low protein infant formula with increased essential amino acids
AU345145S (en) Bottle
AU339376S (en) Sterilizing case
AU337524S (en) Bottle
PH12013500141A1 (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
MY173304A (en) Induction of immune tolerance using methotrexate
AU345141S (en) Bottle
EA201401117A1 (en) COMPOSITIONS CONTAINING PROBIOTICS AND COMPLEX OF BEE POULTRY / CLAY, METHOD OF THEIR PREPARATION AND THEIR APPLICATION IN FOOD AND THERAPY
EA201590061A1 (en) PHARMACEUTICAL COMPOSITION
BR112017014414A2 (en) pharmaceutical formulation
AU343226S (en) Bottle
CY1118277T1 (en) STABLE PHARMACEUTICAL FORM PEXIGANANIS
GT201300058A (en) ANTI-VEGFR-3 ANTIBODY COMPOSITIONS
EA201400444A1 (en) DERIVATIVES 2-OXOPYPERIDINYL
UA112488C2 (en) THREE (HETERO) ARILPYRAZOLES AND THEIR APPLICATIONS
EA201491455A1 (en) EFFECTORS β-ARRESTINA, COMPOSITIONS, THEIR CONTAINING, AND METHODS OF THEIR USE